Xvivo Perfusion AB

Xvivo Perfusion AB is a medical technology company specializing in organ perfusion solutions, enhancing organ viability for transplantation through innovative products designed to improve patient outcomes. Founded in 1998 and headquartered in Gothenburg, Sweden, Xvivo Perfusion AB develops advanced organ perfusion systems to extend the preservation of organs for transplantation. The company has not undergone any significant pivots in its business strategy. Christoffer Rosenblad is the current CEO.

Xvivo Perfusion AB focuses on organ perfusion technology, offering products such as the XPS™ (Ex Vivo Perfusion System) and the STEEN Solution™. These solutions are designed to maintain and assess the viability of organs, thereby improving transplant outcomes. Xvivo caters to hospitals, transplant centers, and research institutions in North America, Europe, and parts of Asia, addressing the critical shortage of available organs for transplant. In 2022, Xvivo Perfusion AB generated revenue of USD 1.

81 mn with an EBITDA of USD -495,627. 4. Their revenue model is centered on direct sales of organ perfusion products and services to healthcare facilities, including agreements for bulk purchases and ongoing support contracts. Xvivo Perfusion AB aims to expand its product line with new organ preservation technologies designed for upcoming healthcare needs.

The company is also targeting expansion into new geographic markets, including Asia and Latin America, by the end of 2024. Recent funding will be utilized to support the development and launch of these new products, as well as to facilitate entry into these new markets.